Last reviewed · How we verify
Mucodyne (carbocysteine)
Mucodyne (generic name: carbocysteine) is a Mucolytic drug. It is currently FDA-approved for Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD), Bronchiectasis (mucus clearance). Also known as: carbocisteine, Mucodyne, S-carboxymethylcysteine.
Mucodyne, also known as carbocysteine, is a small molecule with an unknown mechanism of action. It is used as a mucolytic to reduce the viscosity of sputum, helping to relieve symptoms of conditions such as bronchiectasis and COPD by making it easier to bring up sputum.
At a glance
| Generic name | carbocysteine |
|---|---|
| Also known as | carbocisteine, Mucodyne, S-carboxymethylcysteine |
| Drug class | Mucolytic |
| Target | Mucus glycoprotein synthesis |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD)
- Bronchiectasis (mucus clearance)
Common side effects
Drug interactions
- Antacids
- Cimetidine
- Proton pump inhibitors
- H2-receptor antagonists
- Other mucolytics
Key clinical trials
- Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR) (PHASE3)
- Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients (PHASE2)
- Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup (PHASE1)
- Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children (NA)
- Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis (NA)
- Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis: A Randomized, Multi-center, Double-blind Study (NA)
- Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children. (PHASE4)
- Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mucodyne CI brief — competitive landscape report
- Mucodyne updates RSS · CI watch RSS
Frequently asked questions about Mucodyne
What is Mucodyne?
What is Mucodyne used for?
What is the generic name of Mucodyne?
Is Mucodyne also known as anything else?
What drug class is Mucodyne in?
What development phase is Mucodyne in?
What does Mucodyne target?
Related
- Drug class: All Mucolytic drugs
- Target: All drugs targeting Mucus glycoprotein synthesis
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD)
- Indication: Drugs for Bronchiectasis (mucus clearance)
- Also known as: carbocisteine, Mucodyne, S-carboxymethylcysteine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing